Notes in 4. Hodgkin lymphoma

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	Haem \| HL \| 1.1 \| Epidemiology \| Describe the epidemiology of Hodgkin Lymphoma
Published	02/18/2024	Haem \| HL \| 1.2 \| Aetiology and risk factors \| Describe the aetiology and risk factors for Hodgkin Lymphoma
Published	02/18/2024	Haem \| HL \| 1.3 \| Presentation \| Describe the clinical presentation of hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 1.4.1 \| Workup \| Describe your workup for suspected hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 1.5.1 \| Pathologic classification \| List the subtypes in the WHO classification of Hodgkin Lymphoma
Published	02/18/2024	Haem \| HL \| 1.5.2 \| Pathologic Classification \| Create a table comparing the features of Classical HD vs. Nodular Lymphocyte Predominant Hodgkin Lymph…
Published	02/18/2024	Haem \| HL \| 1.5.3.1 \| Pathologic classification \| Classic HL \| Describe the histopathologic features of classical hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 1.5.4 \| Pathologic classification \| Nodular lymphocyte predominant Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 1.6\| Staging \| Discribe  the Lugano classification (Costwald's modification of Ann Arbor) for staging for Hodgkin Lymphoma
Published	02/18/2024	Haem \| HL \| 1.7 \| Natural history \| Describe the natural history of Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 1.8 \| Differential diagnosis \| Give a differential diagnosis for a patient presenting with clinical features consistent with hodgkin lymph…
Published	02/18/2024	Haem \| HL \| 1.9.3 \| Prognostic factors \| PET response assessment \| List the Deuveille criteria for PET response assessment
Published	02/18/2024	Haem \| HL \| 2.1.1 \| Management \| Overview \| Provide your overview for the management of Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 2.1.1.1 \| Management \| Overview \| Provide your overview for the management of classical Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 2.1.1.2 \| NLPHL \| Management \| Overview \| Provide your overview for the management of nodular lymphocyte predominant Hodgkin lym…
Published	02/18/2024	Haem \| HL \| 2.1.1 \| Management \| RT indications in advanced stage
Published	02/18/2024	Haem \| HL \| 1.5.3.2 \| Pathologic classification \| cHL \| Nodular sclerosis \| Describe the features of nodular sclerosis HL
Published	02/18/2024	Haem \| HL \| 1.5.3.3 \| Pathologic classification \| cHL \| Mixed cellularity \| Describe the features of mixed cellularity classical hodgkin lymphoma (MCC…
Published	02/18/2024	Haem \| HL \| 1.5.3.4 \| Pathologic classification \| cHL \| Lymphocyte rich \| Describe the features of lymphocyte rich classical hodgkin lymphoma (LRCHL)
Published	02/18/2024	Haem \| HL \| 1.5.3.5 \| Pathologic classification \| cHL \| Lymphocyte depleted \| Describe the features of lymphocyte depleted classical hodgkin lymphoma …
Published	02/18/2024	Haem \| HL \| 1.5.1.2 \| Pathologic classification \| Reed-sternberg cell \| Describe the morphology of Reed-Sternberg cells [more for reference than for m…
Published	02/18/2024	Haem \| HL \| 2.1.3 \| Early stage \| Combined modality therapy vs. chemotherapy alone \| Discuss the selection of combined modality therapy vs. chemothera…
Published	02/18/2024	Haem \| HL \| 2.1.3.1 \| Management \| Key trials \| Create a table to define the eligibility criteria of each of the following trials and list the best pe…
Published	02/18/2024	Haem \| HL \| 2.2.1.1 \| Principles of chemotherapy \| ABVD \| List the agents in ABVD chemotherapy
Published	02/18/2024	Haem \| HL \| 2.2.2.1 \| Principles of chemotherapy \| BEACOPP \| List the agents in BEACOPP chemotherapy
Published	02/18/2024	Haem \| HL \| 2.2.3 \| Principles of chemotherapy \| Stanford V \| List the agents in Stanford V chemotherapy
Published	02/18/2024	Haem \| HL \| 2.2.4.1 \|  Principles of chemotherapy \| MOPP \| List the agents in MOPP chemotherapy
Published	02/18/2024	Haem \| HL \| 2.2.1.2 \| Principles of chemotherapy \| ABVD \| How is ABVD chemotherapy given?
Published	02/18/2024	Haem \| HL \| 2.2.2.2 \| Principles of chemotherapy \| BEACOPP \| How is BEACOPP chemotherapy given?
Published	02/18/2024	Haem \| HL \| 2.2.5 \| Principles of RT \| Field definition \| Briefly define extended field RT, Involved field RT, Involved node RT and involved site RT
Published	02/18/2024	Haem \| HL \| 2.1.2 \| Historical perspective \| Give a brief overview of the history of the management of Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 2.1.3.2.2 \| Management \| Key trials \| Early Favourable \| GSHG HD10; NEJM 2010 \| Describe the GHSG HD10 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.4.1 \| Management \| Key trials \| Early favourable/unfavourable \| UK NCRI RAPID; NEJM 2015 \| Describe the RAPID trial
Published	02/18/2024	Haem \| HL \| 2.1.3.4.2 \| Management \| Key trials \| Early favourable/unfavourable \| EORTC H10; JCO 2017 \| Describe the EORTC H10 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.3.2 \| Management \| Key trials \| Early unfavourable \| GHSG HD11; JCO 2010 \| Describe the GHSG HD11 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.6 \| Management \| Key trials \| Early unfavourable / Advanced \| RATHL; NEJM 2016 \| Describe the RATHL trial
Published	02/18/2024	Haem \| HL \| 2.1.2.2 \| Historical perspective \|  Early stage (I-II) favourable cHL \| Briefly describe the (now obsolete) role of staging lapa…
Published	02/18/2024	Haem \| HL \| 2.2.6.1 \| PET \| Briefly list the roles of PET in the management of HL
Published	02/18/2024	Haem \| HL \| 2.2.6.2 \| PET \| Discuss the role of PET in staging HL
Published	02/18/2024	Haem \| HL \| 2.2.6.3 \| PET \| Discuss the prognostic significance of post-chemotherapy PET scans in HL
Published	02/18/2024	Haem \| HL \| 2.2.6.4 \| PET \| Discuss the prognostic significance of interim PET in Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 2.2.6.5 \| PET \| Discuss the role of adapted therapy based on interim PET in Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 2.1.3.2.4 \| Management \| Key trials \| Early Favourable \| GHSG HD16; JCO 2019 \| Describe the GHSG HD 16 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.3.3 \| Management \| Key trials \| Early unfavourable \| GHSG HD14; JCO 2012 \| Describe the GHSG HD14 trial
Published	02/18/2024	Haem \| HL \| 1.4.2 \| Discuss the role of bone marrow biopsy in the workup of patients with newly-diagnosed Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 2.1.3.3.4 \| Management \| Key trials \| Early unfavourable \| GHSG HD17 \| Describe the GHSG HD17 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.5.2.1 \| Management \| Key trials \| Advanced \| BEACOPPesc approach \| GHSG HD 9; NEJM 2003 \| Briefly describe the GHSG HD 9 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.5.2.2 \| Management \| Key trials \| Advanced \| BEACOPPesc approach \| GHSG HD12; JCO 2011 \| Briefly describe the GHSG HD12 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.5.2.3 \| Management \| Key trials \| Advanced \| BEACOPPesc approach \| GHSG HD15; Lancet 2012 \| Briefly describe the GHSG HD15 tria…
Published	02/18/2024	Haem \| HL \| 2.1.3.5.2.4 \| Management \| Key trials \| Advanced \| BEACOPPesc approach \| GHSG HD18; Lancet 2017 \| Briefly describe the GHSG HD18 tria…
Published	02/18/2024	Haem \| HL \| 2.1.3.3.1 \| Management \| Key trials \| Early unfavourable \| GHSG HD8; JCO 2003 \| Describe the GHSG HD8 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.2.1 \| Management \| Key trials \| Early Favourable \| GSHG HD7 (JCO 2007) \| Briefly describe the GHSG HD7 trial
Published	02/18/2024	Haem \| HL \| 2.1.3.5.1.1 \| Management \| Key trials \| Advanced \| ABVD approach \| CALGB trial NEJM 1992 \| Briefly describe the CALGB trial which establis…
Published	02/18/2024	Haem \| HL \| 2.1.3.5.1.2 \| Management \| Key trials \| Advanced \| ABVD approach \| ABVD vs. BEACOPP Italian RCT NEJM 2011 \| Briefly describe the Italian R…
Published	02/18/2024	Haem \| HL \| 2.1.3.5.3.1 \| Management \| Key trials \| Advanced \| Stanford V approach \| Stanford series (non-randomised) Horning, JCO 2002 \| Describe the…
Published	02/18/2024	Haem \| HL \| 2.1.3.5.3.2 \| Management \| Key trials \| Advanced \| Stanford V approach \| UK NCRI Lymphoma Group Study; JCO 2009 \| Briefly describe the UK …
Published	02/18/2024	Haem \| HL \| 2.1.3.5.3.3 \| Management \| Key trials \| Advanced \| Stanford V approach \| ECOG E2496 study; JCO 2012 \| Briefly describe the ECOG E2496 stud…
Published	02/18/2024	Haem \| HL \| 2.1.3.2.0 \| Management \| Key trials \|  Early Favourable (by GHSG criteria) \| Overview \| Briefly summarise the key trials that define …
Published	02/18/2024	Haem \| HL \| 2.1.3.3.0 \| Management \| Key trials \| Early unfavourable \| Overview \| Briefly summarise the key trials that define standard of care treatm…
Published	02/18/2024	Haem \| HL \| 2.1.3.5.1.0 \| Management \| Key trials \| Advanced \| Overview \| Briefly summarise the key trials that define standard of care management in …
Published	02/18/2024	Haem \| HL \| 2.1.3.2.3 \| Management \| Key trials \| Early Favourable \| GHSG HD13; Lancet 2015 \| Describe the GHSG HD 13 trial
Published	02/18/2024	Haem \| HL \| 3.1 \| RT planning \| Early stage HL \| Describe your treatment technique for early stage classical HL
Published	02/18/2024	Haem \| HL \| 3.2 \| RT planning \| Advanced stage HL \| Describe your treatment technique for advanced stage classical HL
Published	02/18/2024	Haem \| HL \| 3.5.1 \| Special issues \| Pregnancy \| Discuss the workup and management of Hodgkin lymphoma in a pregnant patient
Published	02/18/2024	Haem \| HL \| 3.4.2 \| Special issues \| Follow up \| Describe an appropriate follow up schedule for HL
Published	02/18/2024	Haem \| HL \| 3.4.1 \| Special issues \| Late toxicity \| Discuss late toxicities of treatment for Hodgkin lymphoma
Published	02/18/2024	Haem \| HL \| 2.2.1.3 \| Principles of chemotherapy \| ABVD \| Side effects \| List common side effects of ABVD chemotherapy by drug
Published	02/18/2024	Haem \| HL \| 2.2.2.3 \| Principles of chemotherapy \| BEACOPP \| Side effects\|  \| List the side effects of BEACOPP chemotherapy by agent
Published	02/18/2024	Haem \| HL \| 2.2.4.2 \|  Principles of chemotherapy \| MOPP \| List the side effects of MOPP chemotherapy
Published	02/18/2024	Haem \| HL \| 4.1 \| Relapsed and refractory cHL \| Define 'relapsed' and 'refractory' HL; how common are these scenarios
Published	02/18/2024	Haem \| HL \| 4.2 \| Relapsed and refractory cHL \| Discuss the prognosis of relapsed and refractory HL and prognostic factors
Published	02/18/2024	Haem \| HL \| 4.4 \| Relapsed and refractory cHL \| Discuss the rationale and evidence for including RT in the management of relapsed and refractory HL
Published	02/18/2024	Haem \| HL \| 4.3 \| Relapsed and refractory cHL \| Briefly describe a general approach to the management of relapsed and refractory HL and draw a managem…
Published	02/18/2024	Haem \| HL \| 4.5 \| Relapsed and refractory cHL \| List the general indications for including RT as part of a salvage regimen for relapsed and refractory…
Published	02/18/2024	Haem \| HL \| 4.6 \| Relapsed and refractory cHL \| Timing of RT \| Discuss the timing of radiotherapy when used in the setting of relapsed and refractory …
Published	02/18/2024	Haem \| HL \| 4.7 \| Relapsed and refractory cHL \| Refractory \|  List the dose, volume and timing for RT used in the setting of refractory cHL
Published	02/18/2024	Haem \| HL \| 4.8 \| Relapsed and refractory cHL \| Relapsed \| List the dose, volume and timing for RT used in the setting of relapsed cHL
Published	02/18/2024	Haem \| HL \| 4.9 \| Relapsed and refractory cHL \| Transplant ineligible \| List the dose, volume and timing for RT used in the setting of refractory in a…
Published	02/18/2024	Haem \| HL \| 4.9.1 \| Relapsed and refractory cHL \| nLPHL \| List the dose, volume and timing for RT used in the setting of relapsed nodular lymphocyte p…
Published	02/18/2024	Haem \| HL \| 4.9.2 \| Relapsed and refractory cHL \| Palliative RT \| Briefly discuss the role of palliative RT in relapsed and refractory HL
Published	02/18/2024	Haem \| HL \| 4.9.3 \| Relapsed and refractory cHL \| TBI \| Briefly discuss the role of TBI in relapsed and refractory HL
Published	02/18/2024	Haem \| HL \| 3.3 \| Outcomes \| Describe the expected survival outcomes for HL by stage
Published	02/18/2024	Haem \| HL \| 3.5.2 \| Special issues \| Fertility \| Discuss the management of fertility in a young patient with HL
Published	02/18/2024	Haem \| HL \| 2.1.1.1.2 \| Management \| Overview \| When not to use RT \| Give a brief list of patients in whom you would avoid using RT for HL
Published	02/18/2024	Haem \| Hodgkin lymphoma \| x.x \| Pathogenesis
Published	02/18/2024	Haem \| HL \| 3.5.3 \| Special issues \| HIV \| Describe the relationship between HIV infection and Hodgkin’s lymphoma
Status	Last Update	Fields